Intra-Arterial Thrombolysis Within Three Hours of Stroke Onset in Middle Cerebral Artery Strokes

Department of Radiology and Neurology, College of Medicine, The Ohio State University Medical Center, 623 Means Hall, 1654 Upham Dr., Columbus, OH 43210, USA.
Neurocritical Care (Impact Factor: 2.44). 03/2009; 11(2):217-22. DOI: 10.1007/s12028-009-9198-8
Source: PubMed


The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial showed improved outcomes in patients with proximal middle cerebral artery (MCA) occlusions treated with intra-arterial (IA) thrombolysis within 6 h of stroke onset. We analyzed outcomes of patients with proximal MCA occlusions treated within 3 h of stroke onset in order to determine the influence of time-to-treatment on clinical and angiographic outcomes in patients receiving IA thrombolysis.
Thirty-five patients from three academic institutions with angiographically demonstrated proximal MCA occlusions were treated with IA thrombolytics within 3 h of stroke onset. Outcome measures included outcomes at 30-90 day follow-up, recanalization rates, incidence of symptomatic intracranial hemorrhage, and mortality in the first 90 days. The endpoints were compared to the IA treated and control groups of the PROACT II trial.
The median admission National Institutes of Health Stroke Scale (NIHSS) score was 16 (range 4-24). The mean time to initiation of treatment was 106 min (range 10-180 min). Sixty-six percent of patients treated, had a modified Rankin Scale (mRS) score of 2 or less at 1-3 month follow-up compared to 40% in the PROACT II trial. The recanalization rate was 77% (versus 66% in PROACT II). The symptomatic intracranial hemorrhage rate was 11% (versus 10% in PROACT II) and the mortality rate was 23% (versus 25% in PROACT II).
Time-to-treatment is just as important in IA thrombolysis as it is in IV thrombolysis, both for improving clinical outcomes and recanalization rates as well.

14 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: First Page of the Article
    Solid-State Circuits Conference. Digest of Technical Papers. 1965 IEEE International; 03/1965
  • [Show abstract] [Hide abstract]
    ABSTRACT: David Kendrick (1976) has recently suggested that dynamic control schemes which economists have applied to macroeconomic models generally rest on the stringent assumption that monetary and fiscal policy are executed with the same frequency. Kendrick observes: ‘The Federal Reserve Board can make monetary policy decisions fairly quickly. However, fiscal decisions are made by the President, but must then go to Congress, and back to the President. No control theory application has yet taken account of the difference in timing between the policy-making actions.’ This paper recognizes that agents having non-identical control intervals are involved in controlling the macroeconomy and examines the role of monetary and fiscal policies in this context.
    Journal of Economic Dynamics and Control 02/1980; 2(1):377-393. DOI:10.1016/0165-1889(80)90071-8 · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reperfusion of the ischemic territory forms the basis of most acute stroke treatments. This overview of the literature relating to reperfusion in acute ischemic stroke published within the last year provides a snapshot of a rapidly evolving aspect of cerebrovascular disease. Arterial revascularization from systemic thrombolysis to combination endovascular procedures to achieve recanalization has proliferated. Stroke imaging continues to discern features of critical pathophysiology that may influence tissue fate and clinical outcome. Balancing the risk of hemorrhagic transformation against the therapeutic aim to salvage the ischemic penumbra remains a formidable challenge. Collateral therapeutics that enhance perfusion outside the ischemic core present novel dimension to acute stroke therapy, focused on ischemia and not just the clot or plaque. These timely findings illustrate the essential role of reperfusion in acute stroke, delineating aspects of arterial revascularization and collateral therapeutics to be refined in coming years.
    Current opinion in neurology 11/2009; 23(1):36-45. DOI:10.1097/WCO.0b013e328334da32 · 5.31 Impact Factor
Show more